The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).
Toni K. Choueiri
Research Funding - TRACON Pharma
Edwin M. Posadas
Research Funding - TRACON Pharma
Guru Sonpavde
Research Funding - TRACON Pharma
Robert A. Figlin
Research Funding - TRACON Pharma
Meghara K. Walsh
Research Funding - TRACON Pharma
Kevin C. Wall
Research Funding - TRACON Pharma
Ben K. Seon
No relevant relationships to disclose
Manoj A. Jivani
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Bonne J. Adams
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Charles P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma